CS
CRSP icon

Credit Suisse’s CRISPR Therapeutics CRSP Stock Holding History

Credit Suisse’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$49M Sell
719,309
-156,836
-18% -$11.2M 0.05% 378
2023
Q4 		$54.8M Buy
876,145
+3,214
+0.4% +$178K 0.05% 360
2023
Q3 		$39.6M Sell
872,931
-48,725
-5% -$2.52M 0.04% 444
2023
Q2 		$51.7M Buy
921,656
+74,383
+9% +$4.22M 0.05% 397
2023
Q1 		$38.3M Sell
847,273
-5,616
-0.7% -$273K 0.04% 474
2022
Q4 		$34.7M Buy
852,889
+12,183
+1% +$646K 0.04% 508
2022
Q3 		$54.9M Sell
840,706
-82,965
-9% -$6.01M 0.06% 336
2022
Q2 		$56.1M Sell
923,671
-94,156
-9% -$5.54M 0.06% 351
2022
Q1 		$63.9M Sell
1,017,827
-75,625
-7% -$4.75M 0.05% 362
2021
Q4 		$82.9M Buy
1,093,452
+180,911
+20% +$15.8M 0.04% 441
2021
Q3 		$102M Sell
912,541
-48,573
-5% -$6.1M 0.06% 362
2021
Q2 		$156M Buy
961,114
+42,404
+5% +$5.16M 0.08% 248
2021
Q1 		$112M Buy
918,710
+125,266
+16% +$18.9M 0.06% 370
2020
Q4 		$121M Buy
793,444
+91,158
+13% +$10.8M 0.06% 345
2020
Q3 		$58.7M Sell
702,286
-23,624
-3% -$2.1M 0.04% 543
2020
Q2 		$53.3M Sell
725,910
-125,957
-15% -$7.36M 0.04% 512
2020
Q1 		$36.1M Buy
851,867
+130,555
+18% +$6.74M 0.03% 550
2019
Q4 		$43.9M Sell
721,312
-8,516
-1% -$465K 0.03% 618
2019
Q3 		$29.9M Sell
729,828
-68,644
-9% -$3.28M 0.03% 697
2019
Q2 		$37.6M Sell
798,472
-92,092
-10% -$3.68M 0.03% 581
2019
Q1 		$31.8M Buy
890,564
+115,691
+15% +$4M 0.03% 610
2018
Q4 		$22.1M Buy
774,873
+178,821
+30% +$6.22M 0.02% 747
2018
Q3 		$26.4M Buy
596,052
+213,988
+56% +$11.2M 0.02% 728
2018
Q2 		$22.4M Sell
382,064
-64,984
-15% -$3.7M 0.02% 777
2018
Q1 		$20.4M Buy
447,048
+4,203
+0.9% +$173K 0.02% 843
2017
Q4 		$10.4M Buy
442,845
+362,797
+453% +$6.89M 0.01% 1260
2017
Q3 		$1.43M Buy
80,048
+48
+0.1% +$870 ﹤0.01% 2833
2017
Q2 		$1.28M Hold
80,000
– – ﹤0.01% 2539
2017
Q1 		$1.74M Buy
+80,000
New +$1.57M ﹤0.01% 2451

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's CRSP Position: Q1 2024 in Review

Credit Suisse reduced its CRISPR Therapeutics (CRSP) stake by 18% in Q1 2024, selling an estimated $11.2M and leaving 719,309 shares worth $49M. The position accounts for 0.05% of the portfolio, ranked #378.

Credit Suisse first reported a position in CRSP in Q1 2017 and has held it in 29 quarters since. The position peaked at $156M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Credit Suisse held 719,309 shares of CRISPR Therapeutics worth $49M as of Q1 2024.
  • Credit Suisse sold 156,836 CRISPR Therapeutics shares in Q1 2024, an estimated $11.2M.
  • CRISPR Therapeutics made up 0.05% of Credit Suisse's portfolio in Q1 2024, its #378 holding.
  • Credit Suisse first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 29 quarters since.
  • Credit Suisse's CRISPR Therapeutics position peaked at $156M in Q2 2021.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.